Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras

Blood

Volumn 112, Issue 13, 2008, Pages 5245-5253

  Durkin, Emily T ^a   Jones, Kelly A ^a   Rajesh, Deepika ^a   Shaaban, Aimen F ^b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c 1600 JCP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; KLRA1 PROTEIN, MOUSE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY A; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMERA; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FETUS; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IN UTERO STEM CELL TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; ALLOTRANSPLANTATION; ANIMAL; FETUS DISEASE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY; METHODOLOGY; PREGNANCY;

ANIMALS; FEMALE; FETAL DISEASES; FETUS; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNE TOLERANCE; KILLER CELLS, NATURAL; MICE; MODELS, ANIMAL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY A; PREGNANCY; TRANSPLANTATION CHIMERA; TRANSPLANTATION, HOMOLOGOUS;

EID: 58149396862     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-12-128116     Document Type: Article

References (64)

1. Muench MO. In utero transplantation: baby steps towards an effective therapy. Bone Marrow Transplant. 2005;35:537-547.
2. Muench MO, Barcena A. Stem cell transplantation in the fetus. Cancer Control. 2004;11:105-118.
3. Shields LE, Gaur L, Delio P, Potter J, Sieverkropp A, Andrews RG. Fetal immune suppression as adjunctive therapy for in utero hematopoietic stem cell transplantation in nonhuman primates. Stem Cells. 2004;22:759-769.
4. Shields LE, Gaur LK, Gough M, Potter J, Sieverkropp A, Andrews RG. In utero hematopoietic stem cell transplantation in nonhuman primates: the role of T cells. Stem Cells. 2003;21: 304-314.
5. Crombleholme TM, Langer JC, Harrison MR, Zanjani ED. Transplantation of fetal cells [review]. Am J Obstet Gynecol. 1991;164:218-230.
6. Andreoletti M, Le Percq J, Loux N, et al. In utero allotransplantation of retrovirally transduced fetal hepatocytes in primates: feasibility and shortterm follow-up. J Matern Fetal Med. 1998;7:296-303.
7. Peranteau WH, Hayashi S, Hsieh M, Shaaban AF, Flake AW. High-level allogeneic chimerism achieved by prenatal tolerance induction and postnatal nonmyeloablative bone marrow transplantation. Blood. 2002;100:2225-2234.
8. Hayashi S, Peranteau WH, Shaaban AF, Flake AW. Complete allogeneic hematopoietic chimerism achieved by a combined strategy of in utero hematopoietic stem cell transplantation and postnatal donor lymphocyte infusion. Blood. 2002; 100:804-812.
9. Carrier E, Gilpin E, Lee TH, Busch MP, Zanetti M. Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity. J Lab Clin Med. 2000; 136:224-235.
10. Donahue J, Gilpin E, Lee TH, Busch MP, Croft M, Carrier E. Microchimerism does not induce tolerance and sustains immunity after in utero transplantation. Transplantation. 2001;71:359-368.
11. Ferber I, Schönrich G, Schenkel J, Mellor AL, Hämmerling GJ, Arnold B. Levels of peripheral T-cell tolerance induced by different doses of tolerogen. Science. 1994;263:674-676.
12. Hammerling GJ, Schonrich G, Ferber I, Arnold B. Peripheral tolerance as a multi-step mechanism [review]. Immunol Rev. 1993;133:93-104.
13. Kim HB, Shaaban AF, Milner R, Fichter C, Flake AW. In utero bone marrow transplantation induces donor-specific tolerance by a combination of clonal deletion and clonal anergy. J Pediatr Surg. 1999;34:726-729; discussion 729-730.
14. Kim HB, Shaaban AF, Yang EY, Liechty KW, Flake AW. Microchimerism and tolerance after in utero bone marrow transplantation in mice. J Surg Res. 1998;77:1-5.
15. Archer DR, Turner CW, Yeager AM, Fleming WH. Sustained multilineage engraftment of allogeneic hematopoietic stem cells in NOD/SCID mice after in utero transplantation. Blood. 1997;90:3222-3229.
16. Grzywacz B, Kataria N, Sikora M, et al. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood. 2006;108:3824-3833.
17. Wang Y, Xu H, Zheng X, Wei H, Sun R, Tian Z. High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol. 2007;4:377-382.
18. Nassiri M, Viciana A, Streilein JW, Ruiz P. Donor-specific skin transplants activate allodestructive T cells in mice resistant to neonatal H-2 tolerance induction. Transplantation. 1993;56:1460-1467.
19. Ruiz P, Nassiri M, Viciana AL, Padmanabhan J, Streilein JW. Characterization of donor chimerism, alloreactive host T cells and memory cell development in thymi from mice resistant to neonatal transplantation tolerance. J Immunol. 1995; 154:633-643.
20. Streilein JW. Neonatal tolerance of H-2 alloantigens: procuring graft acceptance the old-fashioned way. Transplantation. 1991;52:1-10.
21. Widmer MB, Cooper EL. Ontogeny of cell-mediated cytotoxicity: induction of CTL in early postnatal thymocytes. J Immunol. 1979;122:291-295.
22. Soper BW, Lessard MD, Jude CD, Schuldt AJ, Bunte RM, Barker JE. Successful allogeneic neonatal bone marrow transplantation devoid of my-eloablation requires costimulatory blockade. J Immunol. 2003;171:3270-3277.
23. Fraser KP, Gays F, Robinson JH, et al. NK cells developing in vitro from fetal mouse progenitors express at least one member of the Ly49 family that is acquired in a time-dependent and stochastic manner independently of CD94 and NKG2. Eur J Immunol. 2002;32:868-878.
24. Hanke T, Takizawa H, Raulet DH. MHC-dependent shaping of the inhibitory Ly49 receptor repertoire on NK cells: evidence for a regulated sequential model. Eur J Immunol. 2001;31:3370-3379.
25. Roth C, Carlyle JR, Takizawa H, Raulet DH. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity. 2000;13:143-153.
26. Dorfman JR, Raulet DH. Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med. 1998;187:609-618.
27. Held W, Cado D, Raulet DH. Transgenic expression of the Ly49A natural killer cell receptor confers class I major histocompatibility complex (MHC)-specific inhibition and prevents bone marrow allograft rejection. J Exp Med. 1996;184: 2037-2041.
28. Manilay JO, Waneck GL, Sykes M. Altered expression of Ly-49 receptors on NK cells developing in mixed allogeneic bone marrow chimeras. Int Immunol. 1998;10:1943-1955.
29. Manilay JO, Waneck GL, Sykes M. Levels of Ly-49 receptor expression are determined by the frequency of interactions with MHC ligands: evidence against receptor calibration to a "useful" level. J Immunol. 1999;163:2628-2633.
30. Korten S, Wilk E, Gessner JE, Meyer D, Schmidt RE. Altered donor and recipient Ly49+ NK cell subsets in allogeneic H-2d→H-2b and H-2b→H-2d bone marrow chimeras. J Immunol. 1999;163:5896-5905.
31. Huang Y, Rezzoug F, Xu H, et al. NK cells play a critical role in the regulation of class I-deficient hemopoietic stem cell engraftment: evidence for NK tolerance correlates with receptor editing. J Immunol. 2005;175:3753-3761.
32. Zhao Y, Ohdan H, Manilay JO, Sykes M. NK cell tolerance in mixed allogeneic chimeras. J Immunol. 2003;170:5398-5405.
33. Kase A, Johansson MH, Olsson-Alheim MY Karre K, Hoglund P. External and internal calibration of the MHC class I-specific receptor Ly49A on murine natural killer cells. J Immunol. 1998;161: 6133-6138.
34. Johansson MH, Bieberich C, Jay G, Karre K, Hoglund P. Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med. 1997; 186:353-364.
35. Sentman CL, Olsson MY, Karre K. Missing self recognition by natural killer cells in MHC class I transgenic mice: a "receptor calibration" model for how effector cells adapt to self. Semin Immunol. 1995;7:109-119.
36. Chung DH, Natarajan K, Boyd LF, et al. Mapping the ligand of the NK inhibitory receptor Ly49Aon living cells. J Immunol. 2000;165:6922-6932.
37. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65-78.
38. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004;294: 15-22.
39. Penack O, Gentilini C, Fischer L, et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19:835-840.
40. Westerhuis G, Maas WG, Willemze R, Toes RE, Fibbe WE. Long-term mixed chimerism after immunologic conditioning and MHC-mismatched stem-cell transplantation is dependent on NK-cell tolerance. Blood. 2005;106:2215-2220.
41. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 1997;3:783-787.
42. Bachar-Lustig E, Rachamim N, Li HW, Lan F Reisner Y Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1273.
43. Hajdu K, Tanigawara S, McLean LK, Cowan MJ, Golbus MS. In utero allogeneic hematopoietic stem cell transplantation to induce tolerance. Fetal Diagn Ther. 1996;11:241-248.
44. Nomoto K, Yung-Yun K, Omoto K, et al. Tolerance induction in a fully allogeneic combination using anti-T cell receptor-alpha beta monoclonal antibody, low dose irradiation, and donor bone marrow transfusion. Transplantation. 1995;59:395-401.
45. Quesenberry PJ, Ramshaw H, Crittenden RB, et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells. 1994; 20:348-350.
46. Stewart FM, Crittenden RB, Lowry PA, Pearson-White S, Quesenberry PJ. Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice [see comments]. Blood. 1993;81:2566-2571.
47. Taylor PA, McElmurry RT, Lees CJ, Harrison DE, Blazar BR. Allogenic fetal liver cells have a distinct competitive engraftment advantage over adult bone marrow cells when infused into fetal as compared with adult severe combined immunodeficient recipients. Blood. 2002;99:1870-1872.
48. Ashizuka S, Peranteau WH, Hayashi S, Flake AW. Busulfan-conditioned bone marrow transplantation results in high-level allogeneic chimerism in mice made tolerant by in utero hematopoietic cell transplantation. Exp Hematol. 2006;34: 359-368.
49. Crispe IN, Husmann LA, Bevan MJ. T cell receptor expression and receptor-mediated induction of clonal growth in the developing mouse thymus: high surface beta-chain density is a requirement for functional maturity. Eur J Immunol. 1986;16: 1283-1288.
50. Stites DP, Pavia CS. Ontogeny of human T cells. Pediatrics. 1979;64:795-802.
51. Haynes BF, Denning SM, Singer KH, Kurtzberg J. Ontogeny of T-cell precursors: a model for the initial stages of human T-cell development. Immunol Today. 1989;10:87-91.
52. Royo C, Touraine JL, de Bouteiller O. Ontogeny of T lymphocyte differentiation in the human fetus: acquisition of phenotype and functions. Thymus. 1987;10:57-73.
53. Lindton B, Markling L, Ringden O, Kjaeldgaard A, Gustafson O, Westgren M. Mixed lymphocyte culture of human fetal liver cells. Fetal Diagn Ther. 2000;15:71-78.
54. Renda MC, Fecarotta E, Dieli F, et al. Evidence of alloreactive T lymphocytes in fetal liver: implications for fetal hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25:135-141.
55. Kubota A, Kubota S, Lohwasser S, Mager DL, Takei F Diversity of NK cell receptor repertoire in adult and neonatal mice. J Immunol. 1999;163: 212-216.
56. Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3 epsilon, delta proteins. J Exp Med. 1992;175:1055-1066.
57. Kurepa Z, Hasemann CA, Forman J. Qa-1b binds conserved class I leader peptides derived from several mammalian species. J Exp Med. 1998; 188:973-978.
58. Sivakumar PV, Gunturi A, Salcedo M, et al. Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1 +Ly-49- cells: a possible mechanism of tolerance during NK cell development. J Immunol. 1999;162:6976-6980.
59. Toomey JA, Shrestha S, de la Rue SA, et al. MHC class I expression protects target cells from lysis by Ly49-deficient fetal NK cells. Eur J Immunol. 1998;28:47-56.
60. Manoussaka MS, Smith RJ, Conlin V, Toomey JA, Brooks CG. Fetal mouse NK cell clones are deficient in Ly49 expression, share a common broad lytic specificity, and undergo continuous and extensive diversification in vitro. J Immunol. 1998;160:2197-2206.
61. Manoussaka M, Georgiou A, Rossiter B, et al. Phenotypic and functional characterization of long-lived NK cell lines of different maturational status obtained from mouse fetal liver. J Immunol. 1997;158:112-119.
62. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts: II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med. 1971;134:1513-1528.
63. Le Blanc K, Gotherstrom C, Ringden O, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79:1607-1614.
64. Guillot PV, Gotherstrom C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25:646-654.